Definitive Healthcare Corp. DH R2KPHARMA
Company Overview
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company's platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate firms, financial institutions, marketing and advertising agencies.Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.
Why Investors Should Care
Revenue has grown at a 15.3% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $241.52M (-4.2% YoY); net profit $-138.93M.
- Trailing 12 Months Year-on-year growth — revenue -5.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 15.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 15.34% |
| 1 Year: | -5.50% |
Stock Price Performance
| 1 Year: | -73.35% |
| 6 Months: | -11.02% |
| 3 Months: | +17.06% |
| 1 Month: | +53.28% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)75.69 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 15.3% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 75.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 76 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DH Definitive Healthcare Corp. R2KPHARMA | 1.05 | -0.63 | $110.80M | 0.00% | -38.75% | -75.50% | 15.34% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.07M | 36.94M | 39.82M | 43.08M | 50.12M | 54.55M | 57.38M | 59.20M | 60.96M | 65.33M | 63.48M | 63.74M | 62.70M | 59.19M | 60.75M | 60.05M | 55.93M | 55.20M |
| Gross Profit | 22.66M | 27.50M | 29.95M | 32.60M | 38.80M | 42.77M | 47.66M | 47.30M | 49.79M | 53.43M | 50.38M | 50.45M | 49.03M | 43.76M | 46.61M | 45.99M | 41.65M | 40.54M |
| Operating Income | -940.00K | -2.16M | -6.62M | -4.03M | -10.98M | -11.88M | -10.06M | -12.27M | -12.07M | -295.38M | -16.25M | -369.64M | -225.37M | -184.79M | -4.17M | -8.69M | -201.29M | -6.75M |
| Net Income | - | 0 | 0 | -7.98M | -8.62M | -5.49M | -3.02M | -12.06M | -8.57M | -171.53M | -9.52M | -213.63M | -130.90M | -107.23M | -7.55M | -14.84M | -138.62M | -5.42M |
| Diluted EPS | - | - | - | -0.09 | -0.09 | -0.06 | -0.03 | -0.11 | -0.08 | -1.50 | -0.08 | -1.81 | -1.12 | -0.95 | -0.07 | -0.14 | -1.32 | -0.05 |
| R&D Expense | 2.62M | 3.79M | 4.28M | 4.75M | 6.85M | 8.71M | 9.21M | 9.88M | 10.23M | 10.76M | 10.13M | 10.12M | 7.28M | 9.30M | 7.97M | 7.55M | 6.50M | 6.76M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 118.32M | 166.15M | 222.65M | 251.41M | 252.20M | 241.52M |
| Gross Profit | 87.85M | 125.47M | 180.03M | 203.93M | 197.47M | 183.28M |
| Operating Income | -14.45M | -27.32M | -44.04M | -329.80M | -710.82M | -224.27M |
| Net Income | 0 | -17.84M | -7.22M | -202.39M | -413.12M | -138.93M |
| Diluted EPS | - | -0.19 | -0.07 | -1.79 | -3.54 | -1.30 |
| R&D Expense | 11.06M | 18.57M | 34.89M | 42.44M | 36.52M | 34.78M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Jul 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 1.75B | 2.12B | 2.12B | 1.83B | 1.09B | 735.49M |
| Total Equity | - | - | - | 1.20B | 1.50B | 1.48B | 1.20B | 607.19M | 378.99M |
| Cash & Equivalents | 19.36M | 17.06M | 8.62M | 24.77M | 387.50M | 146.93M | 130.98M | 105.38M | 163.63M |
| Long Term Debt | - | - | - | 457.20M | 263.81M | 255.76M | 242.57M | 229.37M | 156.09M |
| Total Liabilities | - | - | - | 549.80M | 612.73M | 640.68M | 626.73M | 482.19M | 356.50M |
| Current Liabilities | - | - | - | 88.72M | 117.80M | 140.61M | 170.68M | 161.16M | 156.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 23.22M | - | 35.58M | 41.19M | 58.20M | 53.78M |
| Investing Cash Flow | -23.86M | - | -248.90M | -31.78M | -26.41M | 153.88M |
| Financing Cash Flow | 16.66M | - | -26.70M | -25.58M | -56.75M | -150.79M |
| Capital Expenditure | -1.40M | - | -8.33M | -2.98M | -12.34M | -16.72M |
| Free Cash Flow | 21.82M | - | 27.25M | 38.21M | 45.85M | 37.06M |
| Net Change in Cash | - | - | -240.02M | -16.18M | -24.96M | 56.86M |
| Share Buybacks | - | - | 0 | 0 | 22.37M | 49.45M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 74.2% | 75.5% | 80.9% | 81.1% | 78.3% | 75.9% |
| Operating Margin % | -12.2% | -16.4% | -19.8% | -131.2% | -281.8% | -92.9% |
| Net Margin % | 0.0% | -10.7% | -3.2% | -80.5% | -163.8% | -57.5% |
| ROE % | 0.0% | -1.2% | -0.5% | -16.9% | -68.0% | -36.7% |
| ROCE % | -0.9% | -1.4% | -2.2% | -19.9% | -76.6% | -38.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Advent International LP | 58.54% | 62.49M | $50.14M |
| 2 | Goldman Sachs Group Inc | 5.58% | 5.96M | $4.78M |
| 3 | Shaw D.E. & Co., Inc. | 1.85% | 1.97M | $1.58M |
| 4 | Vanguard Capital Management LLC | 1.71% | 1.83M | $1.47M |
| 5 | Kennedy Capital Management, LLC | 1.63% | 1.74M | $1.39M |
| 6 | Dimensional Fund Advisors LP | 1.36% | 1.45M | $1.17M |
| 7 | Blackrock Inc. | 1.32% | 1.41M | $1.13M |
| 8 | Inspire Investing, LLC | 0.84% | 894.95K | $718.11K |
| 9 | AQR Capital Management, LLC | 0.84% | 899.13K | $721.46K |
| 10 | Geode Capital Management, LLC | 0.52% | 550.75K | $441.92K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DH
DH Stock Jumps As AI Platform And EPS Beat Draw Trader Focus - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNcUV4bnJHLUVHSlJMSkp5Vm52d2IzRVI2UWZYQXlvTlBKNzZuWmFiTDhOYlJyajB2dDBJc3l3aThnUUJNM1lsSlNwUml0dGlWa3diLWNoSUtCTWNjTGpXTUJRY015UVdEZ3l2aV9aSnMwRlNuR25CRE1qM3JxcnRVa1FfUQ?oc=5" targe…
DH Stock Steadies As AI Push Offsets Revenue Slide - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPOU52ZXFWLWtXM2E4YzlXdFctbGVuTWE2Qk1rRkVZMWZFUWNoYzhzdzV1ZV9Na1ZVa2F6SlFjd3VHMmFrVm9XdjQwR3d5ek83eUNuQ2pfaFBSVnpPeEMzTVdfVDlkb2JtQUsxT2k3TkVWTGJyeFpKd0s4bFNXRUptV3BR?oc=5" target=…
Definitive Healthcare stock rises on Advent bid (DH:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOejdRRHpQd0tabU5XU3VBZ0Rad3R1UnFvYjJUZzdTUlpMc1Q3dE1fNW9jd0xYOU5aZDRyYjh2d0JPazRHaHRVd3MweE1ueW5jUmZ3S2dlVVlSUGR4UU15S281bi00bXZqTldyVm5QUlRWMmFIRDR6LTVyNFgzUkJETXdMOGRTeEJOT3c?oc…
Definitive Healthcare (DH) CFO stock withheld for RSU taxes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQV3VfUmtiUDBmLVBRYUgzSDVweVpMelMyZ0pZR3N1WEZIUnNFMmZrWkduVHNHSDBWdmswaEdNcHE1bmlaRXN4bFpMM1JSbDROMi0xUGxSZ0JpdnFGNE0yUFFGM0FxaTVBUUlNc3RoanJzWHh3WThicFN6MUpwWi1rUEFsRi0tQmFBTzFPUE…
Definitive Healthcare Corp. (DH) Tops Q1 Earnings Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxORDJ4U1BBa0JPZGdyaWFfbFpDS1VYeTE2Y0dQdkJ4WnVpaVZYbFRhUmNWSktaZnRHTDhtZjMtb09WM3hhOHNfeFViQWE5V3RRdG5sR0dDdWdBVUVyTlV4aWV2Q0JvVExqd0pDcnZ4QnZQY01ZdEV0ekZ6XzloaEk0ZDZzX2FrOEx5ME02UG…
Definitive Healthcare (DH) Stock Price Slides As Revenue Shrinks And Losses Linger - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNNldLa1VzNlBJOE84bVJQU0VTalZmV25qd1BnUTdIZ29famU5MUFFbTlmSWIwRVRjaE5MQUhDUmdnMVlvcXNsMXI2MGZoU1ZQV21kZGNJbHNrbEU1SVZGbGdMbnQ0VXpmZnJBSFBrOXVIS2Q5OXFnSkFmRF93RW5rSk1zWk56UjZ5eGNEQV…
DH — Frequently Asked Questions
What is the current share price of Definitive Healthcare Corp. (DH)?
As of 2026-09-07 16:24 PDT, Definitive Healthcare Corp. (DH) trades at $1.05 on NasdaqGS. Its 52-week range is $0.63 to $4.30.
What is the market capitalisation of DH?
Definitive Healthcare Corp. (DH) has a market capitalisation of $110.80M on NasdaqGS.
What is the P/E ratio of DH?
DH trades at a trailing price-to-earnings (P/E) ratio of -0.63. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.51.
What is the return on equity (ROE) of DH?
DH has a return on equity (ROE) of -75.50%. Its return on capital employed (ROCE) is -38.75%.
Is DH a good stock to buy?
This page provides a data-driven analysis of Definitive Healthcare Corp. (DH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.